

Maryland 20852. Phone: 240-453-6173; email: COVID19HETF@hhs.gov.

SUPPLEMENTARY INFORMATION:

Background: The COVID-19 Health Equity Task Force (Task Force) was established by Executive Order 13995, dated January 21, 2021. The Task Force is tasked with providing specific recommendations to the President, through the Coordinator of the COVID-19 Response and Counselor to the President (COVID-19 Response Coordinator), for mitigating the health inequities caused or exacerbated by the COVID-19 pandemic and for preventing such inequities in the future. The Task Force shall submit a final report to the COVID-19 Response Coordinator addressing any ongoing health inequities faced by COVID-19 survivors that may merit a public health response, describing the factors that contributed to disparities in COVID-19 outcomes, and recommending actions to combat such disparities in future pandemic responses.

The meeting is open to the public and will be live-streamed at www.hhs.gov/live. No registration is required. A public comment session will be held during the meeting. Pre-registration is required to provide public comment during the meeting. To pre-register, please send an email to COVID19HETF@hhs.gov and include your name, title, and organization by close of business on Friday, July 23, 2021. Comments will be limited to no more than three minutes per speaker

and should be pertinent to the meeting discussion. Individuals are encouraged to provide a written statement of any public comment(s) for accurate minute-taking purposes. If you decide you would like to provide public comment but do not pre-register, you may submit your written statement by emailing COVID19HETF@hhs.gov no later than close of business on Thursday, August 5, 2021. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact: COVID19HETF@hhs.gov and reference this meeting. Requests for special accommodations should be made at least 10 business days prior to the meeting.

Dated: July 6, 2021.

Samuel Wu,

Designated Federal Officer, COVID-19 Health Equity Task Force.

[FR Doc. 2021-14703 Filed 7-9-21; 8:45 am]

BILLING CODE 4150-29-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Oligonucleotides Analogues Targeting Human LMNA “lamin A” Gene

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Human Genome Research Institute (NHGRI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive, Sublicensable Patent License to consolidate co-owned rights to the inventions and the Patents and Patent Applications listed in the Supplementary Information section of this notice to The Progeria Research Foundation (“PRF”), having a place of business in 200 Lake Street, Unit 102, Peabody, MA 01960.

DATES: Only written comments and/or applications for a license that are received by the NHGRI Office of Technology Transfer Office on or before July 27, 2021 will be considered.

ADDRESSES: Requests for a copy of the patent application(s), inquiries, and comments relating to the contemplated license should be directed to: Eggerton Campbell, License and Patent Manager, NHGRI Technology Transfer Office, Telephone: 301-402-1648; email: eggerton.campbell@nih.gov.

SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement:

Country	Title	Application No.	Patent No.
United States	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-US-01.	61/568,590.	
WIPO	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-PCT-03.	PCT/US12/068609 WO 2013/086444.	
United Kingdom	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-GB-12.	12806796.4	2788488
United States	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-US-02.	13/708,709	9,326,992
United States	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-US-06.	15/084,255	9,833,468
United States	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-US-07.	15/727,483 CON ..	10,398,721
Europe	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-EP-04.	12806796.4	2788488
Japan	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-JP-15.	2019-109410.	
France	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-FR-11.	12806796.4	2788488
Germany	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-DE-10.	12806796.4	2788488
Ireland	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-IE-13.	12806796.4	2788488
Japan	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-JP-05.	2014-546152	6132849
Japan	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-JP-08.	2017-41744.	
Netherlands	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-NL-14.	12806796.4	2788488
Switzerland	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-CH-09.	12806796.4	2788488
United States	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-US-01	62/330,027.	
WIPO	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-PCT-02	PCT/US17/30174 WO 2017/190041.	

Country	Title	Application No.	Patent No.
United States	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-US-16	16/096,524 (371-national phase).	10,822,608
United States	Oligonucleotide Analogues Targeting Human LMNA	17/024,100.	
Australia	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-AU-03	2017258642.	
Brazil	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-BR-04	BR1120180722790.	
Canada	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-CA-05	3,022,303.	
China	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-CN-06	201780040785.7.	
Colombia	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-CO-07	NC2018/0012783.	
Eurasia	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-EA-08	201892467.	
Europe	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-EP-09	17735676.3.	
Hong Kong	Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-HK-17.	19126894.5.	
India	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-IN-10	201847043433.	
Japan	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-JP-11	2019-508165.	
Korea (South)	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-KR-12	10-2018-7034615.	
Mexico	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-MX-13	MX/A/2018/013157.	
New Zealand	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-NZ-14	747685.	
Singapore	Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-SG-15	11201809468X.	

The patent rights in these inventions have been assigned to the Government of the United States of America, the University of Maryland, Sarepta Therapeutics, Inc, and the Progeria Research Foundation (PRF), co-owners of said rights, for commercial development and marketing. The rights to be granted by NHGRI are controlled by NHGRI by virtue of co-ownership and a license received to the listed intellectual property. The prospective patent license will be for the purpose of consolidating the patent rights to PRF. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200-212. The prospective patent license will be worldwide, exclusive, may be limited to those fields of use commensurate in scope with the patent rights, and will be sublicensable.

The subject technology pertains to modified oligonucleotides (called phosphorodiamidate morpholino oligonucleotides or PMOs) targeted to pre-mRNA of human LMNA Lamin A gene. These PMOs can be used to correct aberrant splicing of LMNA gene known to be involved in Hutchinson-Gilford Progeria Syndrome (HGPS), and could be used in treating this ultra-rare disease and related laminopathies.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective Exclusive Patent License will be royalty bearing and may be granted unless, within fifteen (15) days from the date of this published notice, the NHGRI Technology Transfer Office receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license that are timely filed in response to this notice will be treated as objections to

this to the grant of the contemplated exclusive patent license.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the *Freedom of Information Act*, 5 U.S.C. 552.

Dated: June 29, 2021.

Claire T. Driscoll,

Director, Technology Transfer Office, National Human Genome Research Institute, National Institutes of Health.

[FR Doc. 2021-14702 Filed 7-9-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Mental Health Council.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant

applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Mental Health Council.

Date: August 6, 2021.

Time: 3:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Tracy Lynn Waldeck, Ph.D., Director, Division of Extramural Activities, National Institute of Mental Health, Neuroscience Center, 6001 Executive Boulevard, Room 4133, Rockville, MD 20892, (301) 480-6833, waldeckt@mail.nih.gov.

Information is also available on the Institute's/Center's home page: www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/index.shtml, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

Dated: July 7, 2021.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-14737 Filed 7-9-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council.

The meeting will be closed to the public in accordance with the